Jaguar Health Hosts Investor Webcast on Crofelemer Study Results

Jaguar Health, Inc. will conduct an investor webcast on April 30, 2025, to discuss preliminary results from a proof-of-concept study of crofelemer. This study focuses on treating microvillus inclusion disease (MVID) and short bowel syndrome with intestinal failure (SBS-IF), as presented by Dr. Mohamad Miqdady at the ELITE PED-GI Congress. Currently, there are no approved treatments for MVID, an ultra-rare pediatric disease characterized by severe diarrhea and malabsorption. The webcast will explore patient experiences, crofelemer's effects on disease progression, and potential expedited regulatory pathways.

Crofelemer is a novel plant-based medication derived from the Croton lechleri tree. Jaguar Health, through its subsidiaries Napo Pharmaceuticals and Napo Therapeutics, focuses on developing solutions for gastrointestinal distress and expanding crofelemer access, particularly in Europe. Participants can register online for the webcast.